New roles of osteoblasts involved in osteoclast differentiation

被引:92
作者
Yamashita, Teruhito [1 ]
Takahashi, Naoyuki [1 ]
Udagawa, Nobuyuki [2 ,3 ]
机构
[1] Matsumoto Dent Univ, Inst Oral Sci, 1780 Gobara, Nagano 3990781, Japan
[2] Matsumoto Dent Univ, Dept Biochem, Hirooka, Shiojiri 3990781, Japan
[3] Matsumoto Dent Univ, Dept Biochem, Nagano 3990781, Japan
关键词
Osteoclast; Osteoblast; Receptor activator of nuclear factor-kappa B ligand; Wnt5a; Semaphorin; 3A; Interleukin; 34;
D O I
10.5312/wjo.v3.i11.175
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Bone-resorbing osteoclasts are formed from a monocyte/macrophage lineage under the strict control of bone-forming osteoblasts. So far, macrophage colonystimulating factor (M-CSF), receptor activator of nuclear factor-kappa B ligand (RANKL), and osteoprotegerin (OPG) produced by osteoblasts play major roles in the regulation of osteoclast differentiation. Recent studies have shown that osteoblasts regulate osteoclastogenesis through several mechanisms independent of M-CSF, RANKL, and OPG production. Identification of osteoclast-committed precursors in vivo demonstrated that osteoblasts are involved in the distribution of osteoclast precursors in bone. Interleukin 34 (IL-34), a novel ligand for c-Fms, plays a pivotal role in maintaining the splenic reservoir of osteoclast-committed precursors in M-CSF deficient mice. IL-34 is also able to act as a substitute for osteoblast-producing M-CSF in osteoclastogenesis. Wnt5a, produced by osteoblasts, enhances osteoclast differentiation by upregulating RANK expression through activation of the noncanonical Wnt pathway. Semaphorin 3A produced by osteoblasts inhibits RANKL-induced osteoclast differentiation through the suppression of immunoreceptor tyrosine-based activation motif signals. Thus, recent findings show that osteoclast differentiation is tightly regulated by osteoblasts through several different mechanisms. These newly identified molecules are expected to be promising targets of therapeutic agents in bone-related diseases. (C) 2012 Baishideng. All rights reserved.
引用
收藏
页码:175 / 181
页数:7
相关论文
共 44 条
[1]
Fos plays an essential role in the upregulation of RANK expression in osteoclast precursors within the bone microenvironment [J].
Arai, Atsushi ;
Mizoguchi, Toshihide ;
Harada, Suguru ;
Kobayashi, Yasuhiro ;
Nakamichi, Yuko ;
Yasuda, Hisataka ;
Penninger, Josef M. ;
Yamada, Kazuhiro ;
Udagawa, Nobuyuki ;
Takahashi, Naoyuki .
JOURNAL OF CELL SCIENCE, 2012, 125 (12) :2910-2917
[2]
RANK expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone [J].
Atkins, Gerald J. ;
Kostakis, Panagiota ;
Vincent, Cristina ;
Farrugia, Amanda N. ;
Houchins, Jeffrey P. ;
Findlay, David M. ;
Evdokiou, Andreas ;
Zannettino, Andrew C. W. .
JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 (09) :1339-1349
[3]
OSCAR is a collagen receptor that costimulates osteoclastogenesis in DAP12-deficient humans and mice [J].
Barrow, Alexander David ;
Raynal, Nicolas ;
Andersen, Thomas Levin ;
Slatter, David A. ;
Bihan, Dominique ;
Pugh, Nicholas ;
Cella, Marina ;
Kim, Taesoo ;
Rho, Jaerang ;
Negishi-Koga, Takako ;
Delaisse, Jean-Marie ;
Takayanagi, Hiroshi ;
Lorenzo, Joseph ;
Colonna, Marco ;
Farndale, Richard W. ;
Choi, Yongwon ;
Trowsdale, John .
JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (09) :3505-3516
[4]
Osteoclast differentiation and activation [J].
Boyle, WJ ;
Simonet, WS ;
Lacey, DL .
NATURE, 2003, 423 (6937) :337-342
[5]
osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification [J].
Bucay, N ;
Sarosi, I ;
Dunstan, CR ;
Morony, S ;
Tarpley, J ;
Capparelli, C ;
Scully, S ;
Tan, HL ;
Xu, WL ;
Lacey, DL ;
Boyle, WJ ;
Simonet, WS .
GENES & DEVELOPMENT, 1998, 12 (09) :1260-1268
[6]
Toward an Understanding of the Molecular Mechanisms of Barnacle Larval Settlement: A Comparative Transcriptomic Approach [J].
Chen, Zhang-Fan ;
Matsumura, Kiyotaka ;
Wang, Hao ;
Arellano, Shawn M. ;
Yan, Xingcheng ;
Alam, Intikhab ;
Archer, John A. C. ;
Bajic, Vladimir B. ;
Qian, Pei-Yuan .
PLOS ONE, 2011, 6 (07)
[7]
IL-34 and M-CSF share the receptor Fms but are not identical in biological activity and signal activation [J].
Chihara, T. ;
Suzu, S. ;
Hassan, R. ;
Chutiwitoonchai, N. ;
Hiyoshi, M. ;
Motoyoshi, K. ;
Kimura, F. ;
Okada, S. .
CELL DEATH AND DIFFERENTIATION, 2010, 17 (12) :1917-1927
[8]
Idiopathic hyperphosphatasia and TNFRSF11B mutations:: Relationships between phenotype and genotype [J].
Chong, B ;
Hegde, M ;
Fawkner, M ;
Simonet, S ;
Cassinelli, H ;
Coker, M ;
Kanis, J ;
Seidel, J ;
Tau, C ;
Tüysüz, B ;
Yüksel, B ;
Love, D ;
Cundy, T .
JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 (12) :2095-2104
[9]
Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis [J].
Cohen, Stanley B. ;
Dore, Robin K. ;
Lane, Nancy E. ;
Ory, Peter A. ;
Peterfy, Charles G. ;
Sharp, John T. ;
van der Heijde, Desiree ;
Zhou, Lifen ;
Tsuji, Wayne ;
Newmark, Richard .
ARTHRITIS AND RHEUMATISM, 2008, 58 (05) :1299-1309
[10]
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis [J].
Cummings, Steven R. ;
San Martin, Javier ;
McClung, Michael R. ;
Siris, Ethel S. ;
Eastell, Richard ;
Reid, Ian R. ;
Delmas, Pierre ;
Zoog, Holly B. ;
Austin, Matt ;
Wang, Andrea ;
Kutilek, Stepan ;
Adami, Silvano ;
Zanchetta, Jose ;
Libanati, Cesar ;
Siddhanti, Suresh ;
Christiansen, Claus .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (08) :756-765